EI
IMVT icon

EAM Investors’s Immunovant IMVT Stock Holding History

EAM Investors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-69,241
Closed -$2.24M – 295
2024
Q1 		$2.24M Sell
69,241
-41,688
-38% -$1.52M 0.35% 136
2023
Q4 		$4.67M Buy
110,929
+8,409
+8% +$309K 0.83% 14
2023
Q3 		$3.93M Buy
102,520
+62,724
+158% +$1.42M 0.76% 11
2023
Q2 		$755K Buy
+39,796
New +$742K 0.14% 251
2021
Q1 		– Sell
-32,498
Closed -$1.5M – 389
2020
Q4 		$1.5M Sell
32,498
-2,895
-8% -$134K 0.25% 190
2020
Q3 		$1.25M Buy
+35,393
New +$1.06M 0.3% 153

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM Investors's IMVT Position: Q2 2024 in Review

EAM Investors sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 69,241 shares — an estimated $2.24M sold.

EAM Investors first reported a position in IMVT in Q3 2020 and held it in 6 quarters. The position peaked at $4.67M in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • EAM Investors reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • EAM Investors sold 69,241 Immunovant shares in Q2 2024, an estimated $2.24M.
  • EAM Investors first reported a position in Immunovant in Q3 2020 and held it in 6 quarters.
  • EAM Investors's Immunovant position peaked at $4.67M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.